Results 11 to 20 of about 53,280 (246)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and Therapy, 2022
Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomized phase 2/3/
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen   +14 more
doaj   +1 more source

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. [PDF]

, 2016
IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical ...
DeMasi, Ryan, Fleischmann, Roy M, Huizinga, Tom WJ, Kavanaugh, Arthur F, Kwok, Kenneth, van Vollenhoven, Ronald F, Wilkinson, Bethanie   +6 more
core   +3 more sources

Tofacitinib

DMW - Deutsche Medizinische Wochenschrift, 2014
Tofacitinib is the first Janus kinase inhibitor which was approved for the therapy of rheumatoid arthritis in the USA. Several phase III studies proved the efficacy of Tofacitinib as monotherapy or in combination with established medication. This article discusses the therapeutic potential of this new pharmacological approach and the current data on ...
Doeker, S., Dewenter, Matthias, El-Armouche, Ali   +2 more
openaire   +3 more sources

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

RMD Open, 2022
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lisy Wang, Lara Fallon, Satrajit Roychoudhury, Yves Brault, Meriem Kessouri   +7 more
doaj   +1 more source

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open, 2021
Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Methods Data from two trials ...
Roy Fleischmann, Peter C Taylor, Kurt de Vlam, Joseph C Cappelleri, Alexis Ogdie, Lara Fallon, John Woolcott, Valderilio Azevedo, Andrew G Bushmakin   +8 more
doaj   +1 more source

Tofacitinib [PDF]

Drugs in R&D, 2010
Tofacitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant, is being developed by Pfizer for the treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of transplant rejection.
openaire   +2 more sources

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Arthritis Research & Therapy, 2022
Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib.
Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell   +7 more
doaj   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Possibilities for the use of tofacitinib in patients with COVID-19

Качественная клиническая практика, 2020
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected.
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev   +2 more
doaj   +1 more source

Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
Objective: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia.
Maroun E. Hayek, MD, Michael Mansour, MD, Harrison Ndetan, MPH, MD, PhD, Quentin Burkes, PharmD, Robert Corkern, MD, Ammar Dulli, MD, Reya Hayek, BS, Karim Parvez, MD, Satwinder Singh, MD   +8 more
doaj   +1 more source